trial

A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia

NCTId NCT01942382
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 76 (actual)
Sponsored by Janssen, L.P. - Investigator Initiated Studies Program
Primary completion 2010-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
76 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2009-04
Primary completion
2010-03
Eligibility
ALL · 20 Years · 65 Years

Interventions & indications

Drugs
Paliperidone

Sponsors

Janssen, L.P. - Investigator Initiated Studies ProgramLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
76
Phase
PHASE1
Primary Completion Date
2010-03
Status
COMPLETED
relationships
The graph out of here
drug
Paliperidone
drug
lead_sponsor
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizophrenia
indication